Arcturus Therapeutics Holdings Inc. (ARCT)
After hours:
| Previous Close | 22.98 |
| Open | 23.26 |
| Bid | 24.00 x 100 |
| Ask | 24.10 x 100 |
| Day's Range | 23.26 - 25.17 |
| 52 Week Range | 17.52 - 45.00 |
| Volume | |
| Avg. Volume | 614,688 |
| Market Cap | 648.248M |
| Beta (5Y Monthly) | 2.64 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.03 |
| Earnings Date | Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 77.43 |
Business WireArcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024
SAN DIEGO, July 18, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2024 after the market close on Monday, August 5 and will also host a conference call and webcast at 4:30 pm Eastern Tim
Business WireArcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs
SAN DIEGO, July 01, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today is providing mid-year updates for ARCT-810, an investigational mRNA therapeutic to treat ornithine transcarbamylase (OTC) deficiency, and ARCT-032, an investigational inhaled mRNA therapeutic to treat cy
Business WireArcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors
SAN DIEGO, June 20, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced the appointment of a new independent director, Moncef Slaoui, Ph.D., to the Company's Board of Directors.
